Publications by authors named "Tianzhou Yu"
Article Synopsis
- Lisocabtagene maraleucel (liso-cel) is a CAR T-cell therapy approved in 2022 for treating refractory diffuse large B-cell lymphoma (DLBCL) after first-line therapy, based on positive outcomes from the TRANSFORM study.* -
- A cost-effectiveness analysis showed liso-cel has an incremental cost-effectiveness ratio (ICER) of $99,669 per quality-adjusted life-year (QALY), making it cost-effective under the $100,000 QALY benchmark, though some scenarios exceed this.* -
- The analysis highlights the need to consider productivity losses to better assess the societal value of such treatments, indicating that while liso-cel has clinical
Article Synopsis
- RSV hospitalizations have risen since 2014 due to changing guidelines, prompting the analysis of a new drug, nirsevimab, against palivizumab for preterm infants without additional risk factors.
- A hybrid-Markov model was used to assess the cost-effectiveness of these drugs compared to no prophylaxis, revealing high costs for palivizumab with minimal health benefits.
- The study concluded that neither palivizumab nor nirsevimab is cost-effective for the target group, encouraging a search for more effective and economical alternatives.
Background: Biosimilars have been introduced with the goal of competing with high-priced biologic therapies, yet their adoption has been slower than expected and resulted in limited efficiency gains. We aimed to explore factors associated with biosimilar coverage relative to their reference products by commercial plans in the United States (US).
Methods And Data: We identified 1181 coverage decisions for 19 commercially available biosimilars, corresponding to 7 reference products and 28 indications from the Tufts Medical Center Specialty Drug Evidence and Coverage database.
Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US.
Health Qual Life Outcomes
July 2022
Background: Online longitudinal surveys may be subject to potential biases due to sample attrition. This study was designed to identify potential predictors of attrition using a longitudinal panel survey collected during the COVID-19 pandemic.
Methods: Three waves of data were collected using Amazon Mechanical Turk (MTurk), an online crowd-sourced platform.
Article Synopsis
- The study examined how the COVID-19 pandemic impacted influenza vaccination rates and disparities among different demographic groups by analyzing insurance claims data between 2019 and 2020.
- Influenza vaccination rates rose from 42.3% in late 2019 to 45.9% in late 2020, with notable increases among males and Hispanic individuals, despite lower initial rates among Black and Hispanic populations.
- Disparities were evident based on education levels, with college-educated individuals seeing a substantial increase in vaccinations compared to those with less than a 12th grade education, while poorer individuals consistently had lower vaccination rates.